Interpretation of effect estimates in competing risks survival models: A simulated analysis of organ-specific progression-free survival in a randomised phase III cancer trial
Virdee P., Love S., Dutton P., Moschandreas J.
A presentation encouraging the reporting of all competing risk estimated hazard ratios to provide a more complete picture of the treatment effect on patients